Lynparza approved in Japan for three cancers
29 December 2020 07:00 GMT Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers Approvals based on the PAOLA-1, PROfound and POLO Phase III trials AstraZeneca and MSD's Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers. The three approvals authorise Lynparza for: maintenance treatment after 1st-line chemotherapy containing bevacizumab (genetical recombination) for patients with homologous recombination repair deficient (HRD) ovarian cancer; the treatment of patients